StockData
ArriVent BioPharma, Inc. logo

ArriVent BioPharma, Inc. (AVBP) stock

AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$10.52−0.74 (-6.57%)

Close on Nov 20, 2026Market cap $518.72MP/E –Yield –

ArriVent BioPharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

No free cash flow figures for ArriVent BioPharma

ArriVent BioPharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More ArriVent BioPharma figures

See a number that looks wrong?